Tesamorelin and Liver-Fat Research: Trial Designs and Reported Findings

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

Randomized clinical trials and registry records have evaluated tesamorelin versus placebo for effects on liver fat in people with HIV and hepatic steatosis, using quantitative liver imaging (1H‑MRS) and, in some studies, paired liver biopsies and histologic scoring as prespecified endpoints. Key trials include a 6‑month randomized study and a 12‑month randomized trial with imaging and biopsy endpoints, and subsequent secondary and post‑hoc analyses have characterized histologic and subgroup results. (S8, S6, S7, S9)

Overview of the clinical trial landscape

The evidence base for tesamorelin and liver fat comprises randomized, placebo‑controlled trials registered in trial registries and reported in primary publications; notable entries include a 12‑month randomized, double‑blind trial recorded at NCT02196831 and a prior 6‑month randomized study with an open‑label extension, both enrolling people with HIV and assessing liver fat by 1H‑MRS. (S7, S9, S6, S8) ^{[S7] [S9] [S6] [S8]}

Imaging outcomes: reported changes in liver fat by 1H‑MRS

Quantitative liver fat measured by proton magnetic resonance spectroscopy (1H‑MRS) was the primary imaging endpoint in these trials; in the 12‑month randomized, double‑blind trial of 61 adults with HIV and NAFLD, tesamorelin produced a greater reduction in hepatic fat fraction compared with placebo (reported −4.1% absolute; −37% relative), and in a separate 6‑month randomized trial in HIV patients with abdominal fat accumulation the net treatment effect on hepatic lipid‑to‑water percentage was reported as −2.9% versus placebo. (S6, S8, S7) ^{[S6] [S8] [S7]}

Histology and fibrosis assessments reported alongside imaging

Several trials incorporated liver biopsy endpoints in addition to imaging. The 12‑month randomized trial collected biopsies to evaluate NAFLD Activity Score (NAS) components and fibrosis, and a subsequent secondary analysis of the randomized cohort reported serial biopsies over 12 months to describe histologic endpoints and clinical predictors of fibrosis presence and progression in HIV‑associated NAFLD. (S6, S10) ^{[S6] [S10]}

Trial designs, dosing, populations, and endpoint schedules

The controlled studies were conducted in adults with HIV and hepatic steatosis or abdominal fat accumulation. The 12‑month randomized, double‑blind multicenter trial randomized 61 adults with NAFLD (HFF ≥5% by 1H‑MRS) to tesamorelin 2 mg versus placebo; a separate 6‑month randomized trial used 1H‑MRS as a co‑primary endpoint and included an open‑label extension. Trial registries and primary reports list liver fat by 1H‑MRS as a primary endpoint and liver biopsy (NAS/fibrosis) among secondary endpoints and assessments. (S6, S7, S9, S8) ^{[S6] [S7] [S9] [S8]}

Post‑hoc and subgroup analyses

A post‑hoc analysis leveraged the 61‑participant randomized trial cohort to evaluate efficacy and safety outcomes specifically among participants receiving integrase inhibitor antiretroviral regimens, reporting results relevant to liver fat and metabolic parameters in that subgroup. (S11) ^[S11]

Evidence context and interpretive cautions

The published trials provide randomized evidence of imaging reductions in hepatic fat in people with HIV, accompanied in some studies by paired biopsy data; however, sample sizes are modest (for example, 61 participants in the 12‑month randomized trial), trial durations vary (6 months versus 12 months), and the study populations are people with HIV and NAFLD or abdominal fat accumulation, which limits direct inference to other populations. Secondary and post‑hoc analyses have further explored histologic outcomes and antiretroviral subgroups, but these are derived from the same limited trial cohorts. (S6, S8, S10, S11) ^{[S6] [S8] [S10] [S11]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Evidence is concentrated in people with HIV and hepatic steatosis/abdominal fat accumulation; applicability to non‑HIV populations is not established.
• Sample sizes in the randomized trials are modest (e.g., 61 participants reported in the 12‑month trial), limiting precision for subgroup and long‑term outcome estimation.
• Some protocol details (specific administration route, full dosing schedules beyond the stated 2 mg in registry and primary excerpts) are not fully specified in the reviewed excerpts.
• Longer‑term clinical outcomes beyond 12 months and outcomes in broader clinical populations are not reported in the reviewed sources.

Documentation checklist

• Confirm primary imaging endpoint: hepatic proton magnetic resonance spectroscopy (1H‑MRS)
• Identify histologic endpoints assessed on liver biopsy (NAS and fibrosis)
• Note randomized trials with 6‑month and 12‑month durations in people with HIV
• Extract reported imaging effect sizes (absolute and relative changes) from key trials
• Flag post‑hoc/subgroup analyses (integrase inhibitor exposure) and secondary biopsy analyses
• Assess generalizability given HIV‑specific populations and modest sample sizes

Related research supplies

• 1H‑MRS liver phantom and calibration materials
• MRI‑compatible patient positioning aids and cushions
• Liver biopsy specimen formalin containers and pathology labeling supplies
• Cold‑storage racks for tissue and biobank samples
• Clinical trial case report forms and imaging data transfer log templates

Sources and references

1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
2. [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
3. [S3] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
4. [S4] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin.. Nature reviews. Drug discovery. 2011. PMID: 21283099. DOI: 10.1038/nrd3362
5. [S5] O'Neal R. Tesamorelin update.. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 2010. PMID: 21591600
6. [S6] Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial – PubMed. primary literature
7. [S7] Study Details | NCT02196831 | Tesamorelin Effects on Liver Fat and Histology in HIV | ClinicalTrials.gov. trial registry
8. [S8] Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial – PubMed. primary literature
9. [S9] Study Details | NCT01263717 | Effects of Growth Hormone Releasing Hormone in HIV | ClinicalTrials.gov. trial registry
10. [S10] Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease – PubMed. primary literature
11. [S11] Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors – PubMed. primary literature

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.